Epirubicin Cisplatin and Fluorouracil (FU) Combined With Endostar in Patients With Advanced or Metastatic Gastric Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and tolerability of the ECF regimen
(epirubicin, cisplatin and FU) combined with endostar-- a inhibitor of angiogenesis, in
patients with advanced or metastatic gastric cancer (A/MGC).